ACSS2 and breast carcinoma: Moreover, targeting ACSS2 using CRISPR-Cas9 guides or a small-molecule inhibitor not only hinders tumor cell metabolism but also induces an anticancer immune response, thereby enhancing the effectiveness of chemotherapy in preclinical breast cancer models (177).